Business context and reporting period
This is Neoleukin Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020—not a filing identified in the request metadata as Neurogene Inc. The company develops de novo protein immunotherapies; its lead candidate, NL-201, was in preclinical development. The company reported no product revenue and had no approved products.
Comparisons with Q1 2019 should be read in light of the August 2019 merger and the change in business focus: Q1 2020 spending supported Neoleukin’s development programs, while 2019 costs reflected substantially reduced activity after rosiptor development was halted.
Financial highlights
| Metric | Q1 2020 / March 31, 2020 | Comparable / prior date |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $5.5 million | $0.1 million in Q1 2019 |
| General and administrative expense | $3.6 million | $2.6 million in Q1 2019 |
| Total operating expenses | $9.1 million | $2.7 million in Q1 2019 |
| Other income, net | $0.4 million | $0.5 million in Q1 2019 |
| Net loss | $8.6 million; $0.18 per share | $2.2 million; $0.09 per share in Q1 2019 |
| Cash used in operating activities | $6.4 million | $2.8 million in Q1 2019 |
| Cash and cash equivalents | $139.4 million | $143.1 million at December 31, 2019 |
| Cash, cash equivalents and restricted cash | $139.9 million | Down $3.2 million during the quarter |
| Working capital | $134.1 million | Not stated for the comparable date |
| Total assets / liabilities | $153.1 million / $15.9 million | $147.0 million / $5.3 million at December 31, 2019 |
Net loss per share uses weighted-average shares of 49.2 million, including 10.9 million pre-funded warrants. No meaningful operating margin is available because the company had no product revenue. The company reported an accumulated deficit of $308.2 million.
Q1 financing cash flow was $3.4 million, principally option-exercise proceeds; investing cash use was $0.1 million. The company had no conventional borrowings reported, but lease liabilities totaled $10.7 million, primarily related to its new Seattle facility. Its $0.5 million restricted cash deposit secured a landlord letter of credit.
Material changes and management commentary
- R&D expense rose sharply as NL-201 IND-enabling work and other Neoleukin technology programs advanced; the prior-year quarter reflected rosiptor program suspension and restructuring.
- G&A expense increased, which management attributed primarily to higher staffing and overhead following the merger.
- Management estimated existing cash and cash equivalents would fund operating expenses and capital requirements through 2022, based on its current operating plan. It also said substantial additional capital will be needed over time and may not be available on acceptable terms.
- The company expected to submit an IND for NL-201 by the end of 2020. It said it did not then expect COVID-19 to delay development plans, but acknowledged timing could be affected.
Outlook, risks and unusual items
- COVID-19 prompted a work-from-home policy beginning March 9, 2020, discontinued work travel, and continued business-critical research under safety guidelines. The company shifted planned AACR presentations to a virtual meeting and was exploring possible COVID-19 applications of its technology. It warned that the pandemic could disrupt research, vendors, manufacturing, regulatory work, future clinical trials, and access to capital.
- NL-201 and other candidates remained preclinical; the filing describes substantial clinical, regulatory, manufacturing, safety, intellectual-property, competition, and financing uncertainties. NL-201’s potential safety profile in humans was unknown.
- The new Seattle lease for approximately 33,300 square feet commenced in January 2020, with rent scheduled to begin in December 2020 and a lease term through December 2028. It materially increased recognized right-of-use assets and lease liabilities.
- Management reported effective disclosure controls and no material change in internal control over financial reporting, while noting an ongoing transition of accounting and reporting operations to Seattle. No off-balance-sheet arrangements were reported. The filing describes no specific material legal proceeding.
Important facts for investors to verify
- Confirm the issuer identity: this source is Neoleukin Therapeutics, Inc. (ticker NLTX), not Neurogene Inc.
- Track NL-201 IND-enabling progress, the actual IND submission timing, and any subsequent clinical authorization or delay.
- Assess cash burn against the stated runway through 2022, including whether development spending, lease costs, or COVID-related disruptions change the estimate.
- Review later disclosures for COVID-19 effects on preclinical work, vendors, manufacturing, trial planning, and financing access.
- Monitor dilution and capitalization, including option exercises, pre-funded warrants, and any additional financing.